These studies paved a way of a potential new approach using siRNA conjugated with peptide HBSP or CHBP (a ligand of EPOR/βcR) guided by highly expressed EPOR/βcR on damaged cells including most vulnerable TECs to AKI to achieve delivering siRNA to desired target cells (Black et al., 2022). The gene discussed is EPOR; the disease is acute kidney injury.